Navigation Links
Biogenics Research Chamber Announces Facility Extension
Date:5/9/2013

San Antonio, Texas (PRWEB) May 09, 2013

Biogenics Research Chamber (http://www.biogenicschamber.com), a unique allergy testing facility in San Antonio, Texas, has broken ground on an extension. The 5,400 square feet will house a large allergy exposure chamber, a specialty chamber, and eye examination rooms. The chambers will utilize clean room technology with complete electrical back-up by generator. The extension will enhance capacity for simultaneous testing of large numbers of participants, while broadening therapeutic testing capabilities.

Dr. Robert Jacobs, founder and co-owner, noted that “It is amazing to think that we have outgrown our existing chambers in just three short years. We are excited to be the U.S. leaders in this area of research.”

Biogenics Research Chamber, the only large permanent pollen exposure chamber in the United States, opened in 2010 in the Medical Center of San Antonio. Projects have included pharmaceutical and vaccine trials and scientific studies elucidating the basic mechanisms and genetics of allergy. The extension, scheduled for completion in January 2014, is engineered to challenge with seasonal pollens as well as year-round allergy-provoking agents including dust mites and cat dander. The specialty chamber is designed for testing of novel agents for non-allergic eye and respiratory conditions.

About the Company:
Dr. Robert L. Jacobs, Dr. Daniel A. Ramirez and Dr. Charles P. Andrews are the owners and Principal Investigators of the Biogenics Research Chamber located in San Antonio, Texas. The facility has challenge chambers designed to conduct allergic and non-allergic exposure studies in a controlled environment that utilizes clean room technology. Proof of concept, dose-ranging, and onset of action studies are performed for pharmaceutical and vaccine trials. For companies investigating new products, the chambers offer the advantage of concentrating resources with the potential to shorten medication and vaccine development times.
                                                                    ###

Read the full story at http://www.prweb.com/releases/2013/5/prweb10697751.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. GeneTex Introduces New Mouse Monoclonal Antibody Against the Ten-Eleven Translocation 1 (TET1) Protein for DNA Methylation/Epigenetics Research
2. Core Facility Management Software Company Builds API to Extend Complex Workflows in Research
3. The Alliance for the Advancement of Adult Stem Cell Therapy and Research Recently Has Proven Stem Cells To Be Effective in Dilated Cardiomyopathy
4. Cell Culture Market is Expected to Reach USD 16.85 Billion Globally in 2018: Transparency Market Research
5. Peripheral Vascular Devices Market is Expected to Reach USD 7.8 Billion Globally in 2018: Transparency Market Research
6. Real Time Genomics and J. Craig Venter Institute Embark on Strategic Research Initiative
7. David Hooper Joins Evolution Marketing Research as Senior Director, Research
8. Averica Discovery Services and Worcester Polytechnic Institute Establish Research Collaboration
9. Heptares Achieves All Research Milestones and Receives Milestone Payment From GPCR Drug Discovery Agreement With Takeda
10. Society for Women’s Health Research IMAGINES IT -- SWHR’s Annual Gala Imagines the Future: Information Technology (IT) Transforms Women’s Healthcare
11. Altogen Labs Offers New Pre-Clinical CRO Services to Accelerate Pre-Clinical Research Needs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global ...
Breaking Biology Technology:
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):